Amarin Corporation

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amarin Corporation
Public
Traded as NASDAQAMRN
Industry Biotechnology
Founded 1993
Headquarters Bedminster, New Jersey U.S.
Products Vascepa (AMR-101)
Number of employees
50+
Website www.amarincorp.com
www.vascepa.com

Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD.[1] Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.[2] Recently on July 26, 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval.[3][4] Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.[5]

Products and development[edit]

Amarin's only product is Vascepa, an approved prescription grade Omega-3 fatty acid drug (Ethyl eicosapentaenoic acid) that helps with the management of hypertriglyceridemia. Vascepa's clinical-data trials were the MARINE and ANCHOR studies.

In November 2010, Amarin's MARINE study, which was to treat patients with very high triglycerides (>500 mg/dL), Vascepa showed a decrease in triglycerides. Unlike Vascepa's competitor Lovaza, which can raise median LDL-C from 40% to 50%, Vascepa did not result in a significant increase in median LDL-C.[6]

In April 2011, Amarin's ANCHOR study which was to treat patients with high triglycerides (200 mg/dL to less than 500 mg/dL), Vascepa also displayed a decrease LDL-C. Another unique detail about the ANCHOR study is that Vascepa was able to get approved for the patient population of 200 mg/dL to less than 500 mg/dL, unlike Lovaza which was not approved for this patient population.[7][8]

These studies displayed that Vascepa reduced triglyceride levels and other important lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP.[9]

On 10/16/2013, after FDA's ADCOM panel voted 9-2 against recommending an expanded drug label for Vascepa, for treatment of cardiovascular disease, shares dropped over 60%. As of 02/01/2015 their stock price had not recovered.

Executives[edit]

  • Management Team [10]
  • John Thero: President[10]
  • Aaron Berg: Senior Vice President, Marketing & Sales[11]
  • Joseph T. Kennedy: Senior Vice President, General Counsel and Secretary, Chief Compliance Officer[10]
  • Steven Ketchum: President of Research and Development, Senior Vice President[10]
  • Stuart Sedlack: Senior Vice President, Corporate Development[10]
  • Paresh Soni, M.D., Ph.D.: Senior Vice President and Head of Development[10]
  • Declan Doogan, M.D.: Chief Medical Officer[10]

Board of Directors[edit]

  • Joseph S. Zakrzewski: Chief Executive Officer and Executive Chairman of the Board of Directors[12]
  • Joseph Anderson, Ph.D.: Partner at Abingworth LLP[12]
  • Lars Ekman, Ph.D.: Lead Independent Director, Executive Partner of Sofinnova Ventures[12]
  • Carl L. Gordon, Ph.D., CFA: General Partner and Co-Head of Private Equity of OrbiMed Advisors LLC[12]
  • James Healy, M.D., Ph.D.: General Partner at Sofinnova Ventures, Board Member of Cellective, CoTherix, Novacea, and Intermune.[12]
  • Jan van Heek: Principal and Partner at BioPoint Group[12]
  • Patrick O'Sullivan: Chairman of the Board of Directors of Merrion Pharmaceuticals and as Director of Warner Chilcott Plc.[12]
  • Kristine Peterson: Chief Executive Officer at Valeritas, Inc.[12]

References[edit]

  1. ^ "Amarin Signs Agreement to Acquire Ester Neurosciences - Health News - redOrbit". RedOrbit. 5 December 2007. Retrieved 27 July 2012. 
  2. ^ "Amarin: Mover of the Day - CNBC". April 18, 2011. Retrieved 26 July 2012. 
  3. ^ "Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia". Retrieved 26 July 2012. 
  4. ^ "Amarin Prescription Fish-Oil Pill Approved - TheStreet". Retrieved 26 July 2012. 
  5. ^ "http://www.reuters.com/article/2012/07/26/us-amarin-fda-vascepa-idUSBRE86P1SX20120726". Reuters. 26 July 2012. Retrieved 27 July 2012. 
  6. ^ "Amarin Announces Successful MARINE Phase 3 Clinical Trial Results Published in The American Journal of Cardiology (NASDAQ:AMRN)". Amarin Corp. September 1, 2011. Retrieved 26 July 2012. 
  7. ^ "The Rise Of Amarin's Fish Oil Should Have GSK Worried - Seeking Alpha". Seeking Alpha. Retrieved 21 March 2012. 
  8. ^ "Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C (NASDAQ:AMRN)". Amarin. 18 April 2011. Retrieved 26 July 2012. 
  9. ^ "Amarin's Phase 3 MARINE and ANCHOR Study Data to be Presented at American Heart Association's Scientific Sessions 2011 (NASDAQ:AMRN)". Amarin Corp. 14 November 2011. Retrieved 26 July 2012. 
  10. ^ a b c d e f g "Amarin – Senior Management Team". Retrieved 26 July 2012. 
  11. ^ http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=822991
  12. ^ a b c d e f g h "Amarin – Board Of Directors". Retrieved 26 July 2012. 

External links[edit]